Naseema Gangat, M.B.B.S.

Location

Contact

SUMMARY

The research of Naseema Gangat, M.B.B.S., focuses on myeloid malignancies. These include:

• Myeloproliferative neoplasms.
  • Essential thrombocythemia.
  • Polycythemia vera.
  • Myelofibrosis.
  • Accelerated and blast phase myeloproliferative neoplasms.
• Myelodysplastic syndromes.
• Acute myeloid leukemia.

Her contributions to the management of these conditions include improving prognostication, investigating the connection between mutations and clinical phenotype, and evaluating new treatments.

Focus areas

• Essential thrombocythemia. Dr. Gangat has conducted large observational studies to define the natural history of essential thrombocythemia. She has identified genetic and clinical variables that correlate with long-term outcomes for thrombosis, disease transformation and survival. Dr. Gangat has a special interest in essential thrombocythemia in young women and has developed practice recommendations for managing pregnancy in people with myeloproliferative neoplasms.
• Myelofibrosis. As a clinical researcher, Dr. Gangat has served as the principal investigator of several clinical trials including telomerase inhibitor, aurora-kinase inhibitor, glycogen synthase kinase 3 beta inhibitor and antihemojuvelin antibody trials.
• Accelerated, blast phase myeloproliferative neoplasms. Dr. Gangat researches treatment approaches and outcomes following venetoclax and hypomethylating agent combination therapy.
• Acute myeloid leukemia. Dr. Gangat strives to improve outcome predictions in patients with acute myeloid leukemia treated with venetoclax combination therapy in the real-world setting.

Significance to patient care

Dr. Gangat's research has improved understanding of the long-term outcomes of patients with myeloproliferative neoplasms and acute myeloid leukemia. Her studies serve as a resource for the design and interpretation of future clinical trials in these conditions. In addition, her clinical trial-based investigation has advanced the development of new therapies for myelofibrosis.

Professional highlights

• Associate editor, American Society of Hematology Clinical News, 2022-present.
• Education chair, Division of Hematology, Mayo Clinic, 2022-present.
• Program director, Advanced Hematology Fellowship (Minnesota), Division of Hematology, Mayo Clinic, 2022-present.
• Associate editor, Blood Cancer Journal, 2019-present.
• Clinical Trials Investigator Award, Office of Clinical Trials, Mayo Clinic, 2024.